{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:09:50Z","timestamp":1780920590736,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":74,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011753","name":"National Institute of Immunology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011753","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/4\/2-8\/OH\/2023-NCD-II"],"award-info":[{"award-number":["5\/4\/2-8\/OH\/2023-NCD-II"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101179","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:03:34Z","timestamp":1773677014000},"page":"101179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Towards identification of novel inhibitors of EGFR mutants through in-silico approach"],"prefix":"10.1016","volume":"47","author":[{"given":"Pallavi","family":"Khodlan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajdeep","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabarak","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maninder Pal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Rajbhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101179_bib0001","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101179_bib0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1742-4658.2009.07449.x","article-title":"Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy","volume":"277","author":"Okamoto","year":"2010","journal-title":"FEBS J."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101179_bib0003","first-page":"1547","article-title":"Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: a promising approach","volume":"34","author":"Ribeiro","year":"2014","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101179_bib0004","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.21037\/tlcr-19-359","article-title":"The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer","volume":"9","author":"Zhao","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101179_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.750852","article-title":"Oral squamous cell carcinoma in young patients show higher rates of EGFR amplification: implications for novel personalized therapy","volume":"11","author":"Satgunaseelan","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101179_bib0006","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ctarc.2026.101179_bib0007","first-page":"75","article-title":"The dogma of cetuximab and radiotherapy in head and neck cancer - a dawn to dusk journey","volume":"34","author":"Krishnamurthy","year":"2022","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101179_bib0008","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/172460080001500120","article-title":"Modulation of EGFR gene transcription by a polymorphic repetitive sequence-a link between genetics and epigenetics","volume":"15","author":"Gebhardt","year":"2000","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.ctarc.2026.101179_bib0009","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12098","article-title":"Identification of novel kinase inhibitors by targeting a kinaserelated apoptotic proteinprotein interaction network in HeLa cells","volume":"47","author":"Shi","year":"2014","journal-title":"Cell Prolif."},{"issue":"21","key":"10.1016\/j.ctarc.2026.101179_bib0010","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.3390\/molecules26216677","article-title":"Globally approved EGFR inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism","volume":"26","author":"Abourehab","year":"2021","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101179_bib0011","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1016\/j.bmc.2008.02.053","article-title":"Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR","volume":"16","author":"Michalczyk","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101179_bib0012","first-page":"2005","article-title":"Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion","volume":"35","author":"Banno","year":"2015","journal-title":"Anticancer Res."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101179_bib0013","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/cncr.33385","article-title":"Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a global, phase 2 study","volume":"127","author":"Park","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101179_bib0014","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.3390\/ijms24032651","article-title":"Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities","volume":"24","author":"Zubair","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101179_bib0015","doi-asserted-by":"crossref","first-page":"9234","DOI":"10.1021\/jf9018245","article-title":"Angiotensin-I converting enzyme inhibitory activity of hydrolysates from oat (Avena sativa) proteins by in silico and in vitro analyses","volume":"57","author":"Cheung","year":"2009","journal-title":"J. Agric. Food Chem."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101179_bib0016","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41401-019-0228-6","article-title":"CB-Dock: a web server for cavity detection-guided protein-ligand blind docking","volume":"41","author":"Liu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101179_bib0017","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/ci800293n","article-title":"Validation of molecular docking programs for virtual screening against dihydropteroate synthase","volume":"49","author":"Hevener","year":"2009","journal-title":"J. Chem. Inf. Model."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101179_bib0018","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ctarc.2026.101179_bib0019","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101179_bib0020","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/cmdc.200600155","article-title":"Prediction of ADMET properties","volume":"1","author":"Norinder","year":"2006","journal-title":"ChemMedChem"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101179_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012029","article-title":"Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing","volume":"5","author":"Patil","year":"2010","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101179_bib0022","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"PkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101179_bib0023","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40265-016-0606-z","article-title":"Olmutinib: first global approval","volume":"76","author":"Kim","year":"2016","journal-title":"Drugs"},{"issue":"21","key":"10.1016\/j.ctarc.2026.101179_bib0024","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.3390\/molecules26216423","article-title":"Icotinib, almonertinib, and olmutinib: a 2D similarity\/docking-based study to predict the potential binding modes and interactions into EGFR","volume":"26","author":"Almalki","year":"2021","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101179_bib0025","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.joim.2021.01.001","article-title":"An overview on the chemistry, pharmacology and anticancer properties of tetrandrine and fangchinoline (alkaloids) from Stephania tetrandra roots","volume":"19","author":"Chan","year":"2021","journal-title":"J. Integr. Med."},{"key":"10.1016\/j.ctarc.2026.101179_bib0026","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.phytochem.2016.02.005","article-title":"Tetrandrine\u2013a molecule of wide bioactivity","volume":"125","author":"Bhagya","year":"2016","journal-title":"Phytochemistry"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101179_bib0027","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3892\/mmr.2015.4635","article-title":"Inhibitory effects of tetrandrine on epidermal growth factor-induced invasion and migration in HT29 human colorectal adenocarcinoma cells","volume":"13","author":"Horng","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"23","key":"10.1016\/j.ctarc.2026.101179_bib0028","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.3390\/molecules24234383","article-title":"Tetrandrine interaction with ABCB1 reverses multidrug resistance in cancer cells through competition with anti-cancer drugs followed by downregulation of ABCB1 expression","volume":"24","author":"Liao","year":"2019","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101179_bib0029","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.3390\/molecules27113513","article-title":"Natural products in preventing tumor drug resistance and related signaling pathways","volume":"27","author":"Yang","year":"2022","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101179_bib0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.31276\/VJSTE.65(3).85-90","article-title":"In silico screening of alkaloids as potential inhibitors of epidermal growth factor receptor","volume":"65","author":"Tung","year":"2023","journal-title":"Vietnam J. Sci. Tech. Eng."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101179_bib0031","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1271\/bbb.60.503","article-title":"Early steps of dauricine biosynthesis in cultured roots of Menispermum dauricum","volume":"60","author":"Sugimoto","year":"1996","journal-title":"Biosci. Biotechnol. Biochem."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101179_bib0032","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cbf.3826","article-title":"Dauricine exhibits anti-inflammatory property against acute ulcerative colitis via the regulation of NF-\u03baB pathway","volume":"41","author":"Zhang","year":"2023","journal-title":"Cell Biochem. Funct."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101179_bib0033","first-page":"4403","article-title":"Dauricine suppresses the growth of pancreatic cancer in vivo by modulating the Hedgehog signaling pathway","volume":"18","author":"Zhang","year":"2019","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101179_bib0034","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1039\/D1MO00156F","article-title":"Dauricine inhibits human pancreatic carcinoma cell proliferation through regulating miRNAs","volume":"17","author":"Jiang","year":"2021","journal-title":"Mol. Omics"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:37:38Z","timestamp":1780918658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226000900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":34,"alternative-id":["S2468294226000900"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101179","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards identification of novel inhibitors of EGFR mutants through in-silico approach","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101179"}}